All In Biotech

Drug Trial Radar · NCT04444011

Pharmacokinetic Interactions of Quadruple Therapy With Anaprazole/Amoxicilin/Clarithromycin/Bismuth

A Single-center, Randomized, Open-label, Crossover Study to Evaluate the Pharmacokinetic Drug-drug Interaction of the Quadruple Therapy With Anaprazole/Amoxicilin/Clarithromycin/Bismuth in Healthy Chinese Male Subjects

Last checked: Nov 19, 2026Latest source record: Jun 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

32

Planned (sponsor's estimate)

Start

Jul 1, 2020

Primary completion

Sep 30, 2020

Study completion Oct 15, 2020

Sponsor

Sponsor type
Industry
First posted
Jun 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 35 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A single-center, randomized, open-label, crossover study to evaluate the pharmacokinetic drug-drug interaction and safety of the quadruple therapy with Anaprazole 20mg/Amoxicilin 1000mg/Clarithromycin 500mg/Bismuth Potassium Citrate 0.6g in healthy Chinese male subjects.

Conditions

  • Healthy Male Volunteers

Interventions

  • Anaprazole SodiumDrug

    Anaprazole Sodium isthePPI inhibitor

  • AmoxicillinDrug

    antibiotic

  • ClarithromycinDrug

    antibiotic

  • BismuthDrug

    Bismuth is to protect the gastric mucosa

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Css,max of anaprazole (parent drug, KBP-3571) and its enantiomer(KBP-3570)and its major metabolites (KBP-1123 and KBP-1144), Unchanged amoxicillin, Unchanged clarithromycin and its metabolite (14-hydroxyclarithromycin)Time frame: Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 5,Day 19,Day 33,Day 47
  2. Cohort 1: AUC of anaprazole (parent drug, KBP-3571) and its enantiomer(KBP-3570)and its major metabolites (KBP-1123 and KBP-1144), Unchanged amoxicillin, Unchanged clarithromycin and its metabolite (14-hydroxyclarithromycin)Time frame: Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 5,Day 19,Day 33,Day 47
  3. Cohort 2: Cmax of anaprazole (parent drug, KBP-3571) and its enantiomer(KBP-3570)and its major metabolites (KBP-1123 and KBP-1144), Unchanged amoxicillin, Unchanged clarithromycin and its metabolite (14-hydroxyclarithromycin)Time frame: Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 1,Day 11
  4. Cohort 2: AUC of anaprazole (parent drug, KBP-3571) and its enantiomer(KBP-3570)and its major metabolites (KBP-1123 and KBP-1144), Unchanged amoxicillin, Unchanged clarithromycin and its metabolite (14-hydroxyclarithromycin)Time frame: Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 1,Day 11

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.